MG Biologics

Executive Summary

MG Biologics is a U.S.-based veterinary biologics company specializing in hyperimmune plasma and antibody products for multiple species, including equine, canine, feline, bovine, and porcine. Founded in 2012 and headquartered in Ames, Iowa, the company leverages vaccinated donor animals to produce passive immunity treatments targeting neonatal care, infectious diseases, and critical care. Notably, MG Biologics holds a USDA-licensed antivenom, positioning it as a key player in niche veterinary emergency medicine. The company operates in the growing veterinary biologics market, driven by increasing pet ownership and demand for advanced animal health solutions. As a private entity with no disclosed financials, MG Biologics’ product portfolio and regulatory expertise suggest potential for expansion into new indications and species. However, limited public information on pipeline and revenue constrains assessment of near-term growth trajectory.

Upcoming Catalysts (preview)

• TBDUSDA approval of a new hyperimmune plasma product for emerging equine or canine pathogens40% success
• TBDStrategic partnership or licensing deal with a major animal health company for distribution or co-development35% success